炔雌醇环丙孕酮治疗面部自身免疫性孕酮皮炎32例临床观察

Clinial Observation on 32 Cases of Facial Autoimmune Progesterone Dermatitis Treated with Aethinyloestradiol-Cyproterone

目的观察炔雌醇环丙孕酮片(商品名:达英-35,拜耳先灵医药公司生产)治疗面部自身免疫性孕酮皮炎的临床疗效和安全性。方法入选的32例面部自身免疫性孕酮皮炎患者,在月经第1天开始口服达英-35,每天1片(含醋酸环丙孕酮2mg和炔雌醇0.035mg),连用21d并停用7d为1个疗程,共治疗6个疗程。急性发作期患者同时予西替利嗪片等抗组胺药物口服治疗。自开始用药后第2,4和6个疗程时及停药后第2个疗程时进行随访。结果无脱落病例。治疗第2个疗程时症状体征明显缓解,治疗第2,4和6疗程末其有效率分别为65.63%,84.38%和93.75%。治疗结束后2个疗程时,有2例患者复发,复发率为6.25%。治疗期间有3例患者出现月经紊乱,后随着继续治疗均已逐渐恢复正常;停药后第2个疗程时仅2例患者出现病情反复,但均较治疗前减轻。余未见其他不良反应。结论达英-35治疗面部自身免疫性孕酮皮炎安全而有效。

Objective To investigate the clinical efficacy and safety of aethinyloestradiol-Cyproterone （commercial name： Diane-35, Bayer Schering Pharma Medicines Co ） for the treatment of patients with facial autoim- mune progesterone dermatitis. Methods Thirty-two patients with facial autoimmune progesterone dermatitis were initially treated with Diane-35 one tablet daily（ cyproterone acetate 2rag and ethinylestradiol 0. 035mg） from the first day of menses for 21 days, and then stopped for 7 days as a full course of treatment, with a total of 6 cycles. During the treatment period,anti-histamines including cetirizine were administrated at the acute phase. Follow-up investigations were respectively performed at the 2th cycles,4th cycles,6th cycles of treat- ment and the 2th cycles after the end of treatment. Results All the 32 cases completed the whole course of treatment. The efficacy rates were 65.63% ,84.38% and 93.75% at the 2th cycles,4th cycles,6th cycles after treatment. Two cases relapsed at the 2th cycles after treatment,the recurrence rate was 6.25%. In the whole treatment period, menstrual disorders occurred only in 3 patients and recovered with the continuous therapy. At the 2th cycles after the end of treatment, only 2 patients＂ symptoms appeared recurrence, But its clinical symptoms are relatively mild compared to the symptoms of before treatment. No additional adverse reactions were observed. Conclusion Diane-35 may be a safe and effective treatment option for the patients with facial autoimmune progesterone dermatitis.